Examination of Zolpidem effects on AhR- and PXR-dependent expression of drug-metabolizing cytochromes P450 in primary cultures of human hepatocytes

Toxicology Letters

Volumn 191, Issue 1, 2009, Pages 74-78

  Bachleda, Petr ^a   Vrzal, Radim ^a   Pivnicka, Jakub ^a   Cvek, Boris ^a   Dvorak, Zdenek ^a  

^a PALACKÝ UNIVERSITY   (Czech Republic)

Author keywords

Cytochrome P450; Enzyme induction; Human hepatocytes; Zolpidem

Indexed keywords

AROMATIC HYDROCARBON RECEPTOR; CYTOCHROME P450; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; DIOXIN; MESSENGER RNA; PREGNANE X RECEPTOR; RIFAMPICIN; ZOLPIDEM;

ADULT; AGED; ARTICLE; CELL STRAIN HEPG2; CONTROLLED STUDY; DRUG STRUCTURE; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; LIVER CELL; MALE; PLASMID; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TOXICITY TESTING;

ADULT; AGED; CELLS, CULTURED; CYTOCHROME P-450 ENZYME SYSTEM; HEPATOCYTES; HUMANS; HYPNOTICS AND SEDATIVES; LUCIFERASES; MALE; MIDDLE AGED; PHARMACEUTICAL PREPARATIONS; PLASMIDS; PYRIDINES; RECEPTORS, ARYL HYDROCARBON; RECEPTORS, STEROID; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRANSFECTION;

EID: 70350586837     PISSN: 03784274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.toxlet.2009.08.009     Document Type: Article

References (24)

1. Berson A., Descatoire V., Sutton A., Fau D., Maulny B., Vadrot N., Feldmann G., Berthon B., Tordjmann T., and Pessayre D. Toxicity of alpidem, a peripheral benzodiazepine receptor ligand, but not zolpidem, in rat hepatocytes: role of mitochondrial permeability transition and metabolic activation. J. Pharmacol. Exp. Ther. 299 2 (2001) 793-800
2. Cerveny L., Svecova L., Anzenbacherova E., Vrzal R., Staud F., Dvorak Z., Ulrichova J., Anzenbacher P., and Pavek P. Valproic acid induces CYP3A4 and MDR1 gene expression by activation of constitutive androstane receptor and pregnane X receptor pathways. Drug Metab. Dispos. 35 7 (2007) 1032-1041
3. Drover D.R. Comparative pharmacokinetics and pharmacodynamics of short-acting hypnosedatives: zaleplon, zolpidem and zopiclone. Clin. Pharmacokinet. 43 4 (2004) 227-238
4. Dvorak Z., Vrzal R., Henklova P., Jancova P., Anzenbacherova E., Maurel P., Svecova L., Pavek P., Ehrmann J., Havlik R., Bednar P., Lemr K., and Ulrichova J. JNK inhibitor SP600125 is a partial agonist of human aryl hydrocarbon receptor and induces CYP1A1 and CYP1A2 genes in primary human hepatocytes. Biochem. Pharmacol. 75 2 (2008) 580-588
5. Gerbal-Chaloin S., Pichard-Garcia L., Fabre J.M., Sa-Cunha A., Poellinger L., Maurel P., and Daujat-Chavanieu M. Role of CYP3A4 in the regulation of the aryl hydrocarbon receptor by omeprazole sulphide. Cell Signal 18 5 (2006) 740-750
6. Goodwin B., Hodgson E., and Liddle C. The orphan human pregnane X receptor mediates the transcriptional activation of CYP3A4 by rifampicin through a distal enhancer module. Mol. Pharmacol. 56 6 (1999) 1329-1339
7. Isom H.C., Secott T., Georgoff I., Woodworth C., and Mummaw J. Maintenance of differentiated rat hepatocytes in primary culture. Proc. Natl. Acad. Sci. U.S.A. 82 10 (1985) 3252-3256
8. Luurila H., Kivisto K.T., and Neuvonen P.J. Effect of itraconazole on the pharmacokinetics and pharmacodynamics of zolpidem. Eur. J. Clin. Pharmacol. 54 2 (1998) 163-166
9. Ondra P., Zednikova K., and Matlach R. Possibilities and problems with identification and determination of "new" hypnotics. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub. 149 2 (2005) 469-472
10. Onica T., Nichols K., Larin M., Ng L., Maslen A., Dvorak Z., Pascussi J.M., Vilarem M.J., Maurel P., and Kirby G.M. Dexamethasone-mediated up-regulation of human CYP2A6 involves the glucocorticoid receptor and increased binding of hepatic nuclear factor 4 alpha to the proximal promoter. Mol. Pharmacol. 73 2 (2008) 451-460
11. Pascussi J.M., Gerbal-Chaloin S., Duret C., Daujat-Chavanieu M., Vilarem M.J., and Maurel P. The tangle of nuclear receptors that controls xenobiotic metabolism and transport: crosstalk and consequences. Annu. Rev. Pharmacol. Toxicol. 48 (2008) 1-32
12. Pavek P., Cerveny L., Svecova L., Brysch M., Libra A., Vrzal R., Nachtigal P., Staud F., Ulrichova J., Fendrich Z., and Dvorak Z. Examination of glucocorticoid receptor alpha-mediated transcriptional regulation of P-glycoprotein, CYP3A4, and CYP2C9 genes in placental trophoblast cell lines. Placenta 28 10 (2007) 1004-1011
13. Pfaffl M.W. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 29 9 (2001) e45
14. Pichard-Garcia L., Gerbal-Chaloin S., Ferrini J.B., Fabre J.M., and Maurel P. Use of long-term cultures of human hepatocytes to study cytochrome P450 gene expression. Methods Enzymol. 357 (2002) 311-321
15. Pichard L., Gillet G., Bonfils C., Domergue J., Thenot J.P., and Maurel P. Oxidative metabolism of zolpidem by human liver cytochrome P450S. Drug Metab. Dispos. 23 11 (1995) 1253-1262
16. Sanger D.J. The pharmacology and mechanisms of action of new generation, non-benzodiazepine hypnotic agents. CNS Drugs 18 Suppl. 1 (2004) 9-15 discussion 41, 43-15
17. Schulz M., and Schmoldt A. Therapeutic and toxic blood concentrations of more than 800 drugs and other xenobiotics. Pharmazie 58 7 (2003) 447-474
18. Svecova L., Vrzal R., Burysek L., Anzenbacherova E., Cerveny L., Grim J., Trejtnar F., Kunes J., Pour M., Staud F., Anzenbacher P., Dvorak Z., and Pavek P. Azole antimycotics differentially affect rifampicin-induced pregnane X receptor-mediated CYP3A4 gene expression. Drug Metab. Dispos. 36 2 (2008) 339-348
19. Swainston Harrison T., and Keating G.M. Zolpidem: a review of its use in the management of insomnia. CNS Drugs 19 1 (2005) 65-89
20. US patent 4382938, Kaplan J-P, George P, "Imidazo[1,2-a] pyridine derivatives and their application as pharmaceuticals", granted 1984-07-17, assigned to Synthelabo.
21. Villikka K., Kivisto K.T., Lamberg T.S., Kantola T., and Neuvonen P.J. Concentrations and effects of zopiclone are greatly reduced by rifampicin. Br. J. Clin. Pharmacol. 43 5 (1997) 471-474
22. Villikka K., Kivisto K.T., Luurila H., and Neuvonen P.J. Rifampin reduces plasma concentrations and effects of zolpidem. Clin. Pharmacol. Ther. 62 6 (1997) 629-634
23. von Moltke L.L., Weemhoff J.L., Perloff M.D., Hesse L.M., Harmatz J.S., Roth-Schechter B.F., and Greenblatt D.J. Effect of zolpidem on human cytochrome P450 activity, and on transport mediated by P-glycoprotein. Biopharm. Drug Dispos. 23 9 (2002) 361-367
24. Zammit G. Zolpidem extended-release: therapy for sleep induction and sleep maintenance difficulties. Expert Opin. Drug Metab. Toxicol. 4 3 (2008) 325-331